July 2, 2024

Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer and will be responsible for leading the organization’s growth in preparation for commercial launch of its lead asset, gildeuretinol acetate, as a potential treatment for Stargardt disease. Alkeus Co-Founder Leonide Saad, Ph.D., has been named Chief Scientific Officer and will remain an integral part of the company’s continued development of novel treatments for serious diseases of the eye.

Learn More
May 8, 2024

Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

CAMBRIDGE, Mass. — Alkeus Pharmaceuticals, Inc. today announced the presentation of positive interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic for the duration of therapy ranging between two and six years. Results were presented during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.

Learn More
May 1, 2024

Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Disease Patients During the ARVO 2024 Annual Meeting May 5-9

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. today announced that new positive data from its TEASE-3 clinical trial of gildeuretinol in teenage and young-adult patients with early-stage Stargardt disease will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.

Learn More